219 related articles for article (PubMed ID: 34419967)
1. Update on omalizumab in allergen immunotherapy.
Dantzer JA; Wood RA
Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):559-568. PubMed ID: 34419967
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab as an adjuvant in food allergen immunotherapy.
Dantzer JA; Wood RA
Curr Opin Allergy Clin Immunol; 2021 Jun; 21(3):278-285. PubMed ID: 33605614
[TBL] [Abstract][Full Text] [Related]
3. The use of omalizumab in allergen immunotherapy.
Dantzer JA; Wood RA
Clin Exp Allergy; 2018 Mar; 48(3):232-240. PubMed ID: 29315922
[TBL] [Abstract][Full Text] [Related]
4. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview.
Asaria M; Dhami S; van Ree R; Gerth van Wijk R; Muraro A; Roberts G; Sheikh A
Allergy; 2018 Feb; 73(2):269-283. PubMed ID: 28718981
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP).
De Filippo M; Votto M; Caminiti L; Carella F; Castro G; Landi M; Olcese R; Panasiti I; Vernich M; Barberi S; Ciprandi G; Marseglia GL
Allergol Immunopathol (Madr); 2022; 50(6):47-52. PubMed ID: 36335444
[TBL] [Abstract][Full Text] [Related]
6. The Use of Omalizumab in Food Oral Immunotherapy.
Labrosse R; Graham F; Des Roches A; Bégin P
Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):189-199. PubMed ID: 27628022
[TBL] [Abstract][Full Text] [Related]
7. Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.
Guilleminault L; Michelet M; Reber LL
Clin Rev Allergy Immunol; 2022 Feb; 62(1):216-231. PubMed ID: 34550555
[TBL] [Abstract][Full Text] [Related]
8. Allergen immunotherapy as add-on to biologic agents.
Lombardi C; Canonica GW; Passalacqua G
Curr Opin Allergy Clin Immunol; 2018 Dec; 18(6):502-508. PubMed ID: 30148718
[TBL] [Abstract][Full Text] [Related]
9. Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials.
Zhang YY; Zhang M; Zhang JQ; Li QQ; Lu MP; Cheng L
Int Forum Allergy Rhinol; 2024 Apr; 14(4):794-806. PubMed ID: 37715592
[TBL] [Abstract][Full Text] [Related]
10. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.
Andorf S; Purington N; Block WM; Long AJ; Tupa D; Brittain E; Rudman Spergel A; Desai M; Galli SJ; Nadeau KC; Chinthrajah RS
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):85-94. PubMed ID: 29242014
[TBL] [Abstract][Full Text] [Related]
11. Combining anti-IgE with oral immunotherapy.
Lin C; Lee IT; Sampath V; Dinakar C; DeKruyff RH; Schneider LC; Nadeau KC
Pediatr Allergy Immunol; 2017 Nov; 28(7):619-627. PubMed ID: 28782296
[TBL] [Abstract][Full Text] [Related]
12. Oral immunotherapy and potential treatment.
Sato S; Yanagida N; Ebisawa M
Chem Immunol Allergy; 2015; 101():106-13. PubMed ID: 26022870
[TBL] [Abstract][Full Text] [Related]
13. New Developments in Non-allergen-specific Therapy for the Treatment of Food Allergy.
Long A; Borro M; Sampath V; Chinthrajah RS
Curr Allergy Asthma Rep; 2020 Jan; 20(1):3. PubMed ID: 31950290
[TBL] [Abstract][Full Text] [Related]
14. The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions.
Yee CS; Rachid R
Curr Allergy Asthma Rep; 2016 Apr; 16(4):25. PubMed ID: 26922433
[TBL] [Abstract][Full Text] [Related]
15. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.
Wood RA; Kim JS; Lindblad R; Nadeau K; Henning AK; Dawson P; Plaut M; Sampson HA
J Allergy Clin Immunol; 2016 Apr; 137(4):1103-1110.e11. PubMed ID: 26581915
[TBL] [Abstract][Full Text] [Related]
17. Retail Food Equivalents for Post-Oral Immunotherapy Dosing in the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) Clinical Trial.
Groetch M; Mudd K; Woch M; Schaible A; Gray BE; Babineau DC; Bird JA; Jones S; Kim EH; Lanser BJ; Poyser J; Rogers N; Shreffler W; Sicherer S; Spergel AKR; Spergel J; Vickery BP; Chinthrajah RS; Wood R
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):572-580.e2. PubMed ID: 37113037
[TBL] [Abstract][Full Text] [Related]
18. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose.
Stretz E; Oppel EM; Räwer HC; Chatelain R; Mastnik S; Przybilla B; Ruëff F
Clin Exp Allergy; 2017 Dec; 47(12):1631-1639. PubMed ID: 28802075
[TBL] [Abstract][Full Text] [Related]
19. Molecular approaches to allergen-specific immunotherapy: Are we so far from clinical implementation?
Pechsrichuang P; Jacquet A
Clin Exp Allergy; 2020 May; 50(5):543-557. PubMed ID: 32078207
[TBL] [Abstract][Full Text] [Related]
20. From IgE to clinical trials of allergic rhinitis.
Ciprandi G; Marseglia GL; Castagnoli R; Valsecchi C; Tagliacarne C; Caimmi S; Licari A
Expert Rev Clin Immunol; 2015; 11(12):1321-33. PubMed ID: 26358006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
